FDA could gain new powers next year

11/3/2006 | RPM Report (free registration), The

The FDA could gain several new powers when Congress examines drug safety reforms next year, including greater authority over prescription labels. Other changes could include requiring risk management plans for new drugs, establishing post-market PDUFA goals for safety issues, and clinical trial registration for Phase II, III and IV studies.

View Full Article in:

RPM Report (free registration), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ